New Triple-Threat treatment tested for spreading prostate cancer
NCT ID NCT03246347
Summary
This study is testing whether adding a newer drug called enzalutamide to the standard two-drug treatment (androgen deprivation therapy plus docetaxel chemotherapy) works better for men with prostate cancer that has spread. The goal is to see if this three-drug combination is safe and more effective at controlling the cancer. About 40 men with this advanced stage of prostate cancer will participate to measure how well the treatment lowers their PSA levels over one year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
Conditions
Explore the condition pages connected to this study.